pol Gene Products, Human Immunodeficiency Virus
"pol Gene Products, Human Immunodeficiency Virus" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Proteins encoded by the POL GENE of the HUMAN IMMUNODEFICIENCY VIRUS.
| Descriptor ID |
D054302
|
| MeSH Number(s) |
D12.776.775.360.650 D12.776.964.775.375.545 D12.776.964.775.562.764 D12.776.964.970.600.850.375.545
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "pol Gene Products, Human Immunodeficiency Virus".
Below are MeSH descriptors whose meaning is more specific than "pol Gene Products, Human Immunodeficiency Virus".
This graph shows the total number of publications written about "pol Gene Products, Human Immunodeficiency Virus" by people in this website by year, and whether "pol Gene Products, Human Immunodeficiency Virus" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2009 | 0 | 1 | 1 |
| 2010 | 2 | 2 | 4 |
| 2011 | 0 | 1 | 1 |
| 2012 | 0 | 1 | 1 |
| 2014 | 2 | 1 | 3 |
| 2015 | 0 | 1 | 1 |
| 2016 | 0 | 1 | 1 |
| 2019 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "pol Gene Products, Human Immunodeficiency Virus" by people in Profiles.
-
Detection and molecular characterization of urinary tract HIV-1 populations. Ann Clin Microbiol Antimicrob. 2019 Sep 24; 18(1):27.
-
HIV-1 antiretroviral drug resistance patterns in patients failing NNRTI-based treatment: results from a national survey in South Africa. J Antimicrob Chemother. 2017 01; 72(1):210-219.
-
Pretreatment HIV Drug Resistance and HIV-1 Subtype C Are Independently Associated With Virologic Failure: Results From the Multinational PEARLS (ACTG A5175) Clinical Trial. Clin Infect Dis. 2015 May 15; 60(10):1541-9.
-
Predictors of HVTN 503 MRK-AD5 HIV-1 gag/pol/nef vaccine induced immune responses. PLoS One. 2014; 9(8):e103446.
-
High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. PLoS One. 2014; 9(5):e97067.
-
Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili study. Lancet Infect Dis. 2014 May; 14(5):388-96.
-
HIV-1 subtype distribution trends and evidence of transmission clusters among incident cases in a rural clinical cohort in southwest Uganda, 2004-2010. AIDS Res Hum Retroviruses. 2013 Mar; 29(3):520-7.
-
Rapid development of antiretroviral drug resistance mutations in HIV-infected children less than two years of age initiating protease inhibitor-based therapy in South Africa. AIDS Res Hum Retroviruses. 2011 Sep; 27(9):945-56.
-
Transmitted HIV type 1 drug resistance among individuals with recent HIV infection in East and Southern Africa. AIDS Res Hum Retroviruses. 2011 Jan; 27(1):5-12.
-
Overview of STEP and Phambili trial results: two phase IIb test-of-concept studies investigating the efficacy of MRK adenovirus type 5 gag/pol/nef subtype B HIV vaccine. Curr Opin HIV AIDS. 2010 Sep; 5(5):357-61.